Sagimet Biosciences (SGMT) Oppenheimer 36th Annual Healthcare Life Sciences Conference summary

Strategic focus and pipeline overview

• Lead FASN inhibitor denifanstat targets fat accumulation, inflammation, and fibrosis in MASH, acne, and certain solid tumors, offering a differentiated mechanism from current therapies.

• Phase II studies in MASH showed significant reductions in inflammation and fibrosis, especially in advanced patients, with strong anti-fibrotic effects confirmed by AI digital pathology.

• Combination of denifanstat and resmetirom is advancing to phase II in cirrhotic (qF4) MASH patients, following a successful phase I PK/safety study showing no safety signals.

• In acne, Chinese partner Ascletis achieved statistically significant efficacy and safety in phase III, with regulatory submission accepted and potential approval expected late this year or early next.

• Next-generation FASN inhibitor TVB-3567 is in phase I, with phase II planned by year-end and results expected in the second half of next year.

Clinical data and differentiation

• Denifanstat is the only drug directly targeting all three MASH drivers: fat, inflammation, and fibrosis, with phase II-B meeting both FDA-required primary endpoints.

• AI digital pathology confirmed fibrosis regression, including in cirrhotic patients, supporting the anti-fibrotic mechanism.

• Combination with resmetirom leverages complementary mechanisms, with preclinical synergy and potential for a single oral tablet, aiming for frontline therapy.

• Phase I PK study of the combo showed strong safety and tolerability, with detailed results to be presented at EASL.

• Upcoming phase II will test multiple doses, include comparison arms, and assess non-invasive endpoints over 52–96 weeks.

Competitive landscape and regulatory strategy

• Combination therapy is positioned as a patient-friendly, once-daily oral alternative to injectables, with no observed GI, DILI, bone, or muscle safety issues.

• GLP-1 and FGF21 therapies are seen as complementary, with Denny upregulating FGF21 and adiponectin, further supporting its role in MASH.

• Regulatory engagement is ongoing, with evolving endpoints and acceptance of non-invasive tests anticipated.

• Licensing agreement with TAPI/Teva secures supply and flexibility for resmetirom API in the combination product.